The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Black Diamond Therapeutics Inc shares valued at $11,997,749 were sold by BIOTECH GROWTH N V on Mar 19 ’25. At $2.07 per share, BIOTECH GROWTH N V sold 5,784,292 shares. The insider’s holdings dropped to 2,733,547 shares worth approximately $7.08 million following the completion of this transaction.
Also, Versant Venture Capital VI, L. sold 221,600 shares, netting a total of over 1,400,556 in proceeds. Following the sale of shares at $6.32 each, the insider now holds 3,726,341 shares.
Before that, David Epstein had added 50,000 shares to its account. In a trade valued at $310,000, the Former Employer bought Black Diamond Therapeutics Inc shares for $6.20 each.
As published in their initiating research note from Raymond James on July 31, 2024, Black Diamond Therapeutics Inc [BDTX] has been an Outperform and the price target has been revised to $20. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid July. As of June 30, 2023, Stifel has increased its “Hold” rating to a “Buy” for BDTX. Earlier on June 28, 2023, H.C. Wainwright upgraded its rating. Their new recommendation was “a Buy” for BDTX stock which previously was a “a Neutral”.
Analyzing BDTX Stock Performance
On last trading session,, Black Diamond Therapeutics Inc [NASDAQ: BDTX] rose 4.02% to $2.59. The stock’s lowest price that day was $2.405, but it reached a high of $2.7 in the same session. During the last five days, there has been a surge of approximately 11.64%. Over the course of the year, Black Diamond Therapeutics Inc shares have dropped approximately -46.49%. Shares of the company reached a 52-week high of $2.82 on 01/31/25 and a 52-week low of $1.20 on 04/09/25.
Support And Resistance Levels for Black Diamond Therapeutics Inc (BDTX)
According to the 24-hour chart, there is a support level at 2.42, which, if violated, would cause prices to drop to 2.26. In the upper region, resistance lies at 2.73. The next price resistance is at 2.88. RSI (Relative Strength Index) is 64.84 on the 14-day chart, showing neutral technical sentiment.
Is Black Diamond Therapeutics Inc subject to short interest?
Stocks of Black Diamond Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -1.87 million shares to 7.57 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 9.44 million shares. A decline of -24.68% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.39 of the overall float, the days-to-cover ratio (short ratio) decline to 6.39.
Which companies own the most shares of Black Diamond Therapeutics Inc (BDTX)?
In terms of Black Diamond Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 462.25% from the previous closing price of $2.49. Analysts anticipate Black Diamond Therapeutics Inc stock to reach 20 by 2025, with the lowest price target being 11. In spite of this, 3 analysts ranked Black Diamond Therapeutics Inc stock as Buy at the end of 2025. On June 27, 2023, Wedbush assigned a price target of “an Outperform” to the stock and upgraded coverage with a $10.
